Pfizer Inc has told the Indian government it wants to produce its coronavirus vaccine locally if assured of faster regulatory clearance and
freedom on pricing and exports, two sources with direct knowledge of the matter told Reuters.
The US company pulled an application last month seeking emergency approval for its product in India after the drug regulator declined its request to skip a small local safety trial. That has kept its vaccine, developed with Germany’s BioNTech SE, out of one of the world’s biggest drug markets.
For more coronavirus news, visit our dedicated page.
Pfizer was the first company to apply for emergency use authorization in India, proposing to import doses from its US and European facilities instead of producing locally.
For all the latest headlines follow our Google News channel online or via the app.
“US companies want to produce vaccines in India under joint ventures,” said one of the sources, citing Pfizer and fellow US drugmaker Moderna Inc.
“They want faster approvals for clinical trials and emergency authorization use. They fear the government will introduce price control policies.”
Another source confirmed Pfizer was interested in manufacturing in India but Reuters could not find a second confirmation on Moderna.
The companies did not immediately respond to requests for comment. India’s health ministry directed Reuters to the foreign ministry, which did not immediately respond to emailed queries.
While withdrawing its application in early February, Pfizer said it would again seek emergency use approval to launch its COVID-19 vaccine in India, potentially a market of 1.35 billion people, and would provide more data as it becomes available.
On the government’s demand to manufacture in India, the company earlier told Reuters: “Once the pandemic supply phase is over and we enter a phase of regular supplies, Pfizer will evaluate all additional opportunities available.”
An Indian official told Reuters in January the government had held discussions with Pfizer and Moderna -- both of which have reported more than 90 percent efficacy for their vaccines -- to make the shots in India given its large pharmaceuticals capacity.
The Serum Institute of India, the world’s largest vaccine maker, is already bulk-manufacturing the Oxford University/AstraZeneca product and plans to start producing the Novavax Inc shot from next month.
India’s government has not allowed it to sell on the higher-priced private market, however, and is also controlling exports. Pfizer and Moderna, whose shots are more expensive than the AstraZeneca one being used in India’s immunization campaign, are not comfortable with strict price and export restrictions, one of the sources said.
This week, Reuters reported that leaders of the Quad alliance -- Australia, Japan, India and the United States -- plan to announce financing agreements to increase India’s vaccine manufacturing capacity at their first meeting on Friday.
The initiative will mainly involve production of the Novavax and Johnson & Johnson shots for supplying to regions including Southeast Asia, where their common rival China is making gains.
- Pfizer could have capacity for 3 billion COVID-19 doses in 2022
- New Zealand’s PM says will buy enough Pfizer vaccines to inoculate entire population
- US scientists doubtful of one-shot regimen for Pfizer, Moderna COVID-19 vaccines: WSJ
- Pfizer plant helping boost vaccines has repeat quality offenses
- Fauci says US must stick to two-dose strategy for Pfizer, Moderna vaccines: Report
- UK study shows single Pfizer vaccine dose reduces COVID-19 transmission
- Pfizer studying effects of third COVID-19 vaccine dose
- ‘Real world’ study proves Pfizer vaccine 94 pct effective against COVID-19